Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
NCT01909752
Completed
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2017
Locations: LSU Stanley S. Scott Cancer Center, New Orleans, Louisiana +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT00020670
Terminated
The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having unfavorable genetics \[t(4;11) or t(9;22)\] have dismal prognosis. For these patients, novel therapeutic approaches such as immunotherapy are needed. In this clinical trial, investigators evaluate whether it is feasible to make a vaccine from leukemia cells and whether this va... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/19/2017
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Leukemia
Register for Updates
Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting
NCT01654224
Completed
The purpose of the study is to compare the performance of two currently available influenza (flu) vaccines. This study will try and determine if the high dose flu vaccine provides protection that is the same or better than that of regular dose flu vaccine. Both the regular dose and the high dose flu vaccines are approved by the FDA for use in older adults.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/13/2017
Locations: University of Pittsburgh, Division of Geriatric Medicine, Pittsburgh, Pennsylvania
Conditions: Influenza
Register for Updates
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
NCT01782300
Completed
Dengue viruses can cause dengue fever and other more severe forms of disease. This study will evaluate the safety and immune response to two doses of a dengue virus vaccine given 12 months apart in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/12/2017
Locations: Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland +1 locations
Conditions: Dengue
Register for Updates
Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
NCT01827462
Completed
In this study the investigators are trying to understand how immune function declines in the elderly using annual influenza vaccinations as a model system. The longitudinal study began in 2007 and continued through early 2017.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/09/2017
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Influenza
Register for Updates
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
NCT01999842
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/26/2017
Locations: GSK Investigational Site, Jacksonville, Florida +7 locations
Conditions: Influenza
Register for Updates
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
NCT00856297
Completed
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescents previously enrolled in the V59P13 study who received either Novartis MenACWY Conjugate Vaccine or commercially available MenACWY conjugate vaccine. The study will also enroll age-matched subjects who have never received any other meningococcal vaccine (naïve subjects) to serve as an additional control group.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
05/17/2017
Locations: 37, 50 Birmingham Pediatric Associates 806 Saint Vincent's Drive, Suite 615, Birmingham, Alabama +31 locations
Conditions: Meningococcal Meningitis
Register for Updates
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
NCT00138294
Completed
The main purpose of this study is to learn if influenza vaccines (live attenuated and inactivated influenza vaccines), when given to school-aged children 4 to 18 years of age, can stop or lessen the influenza (flu) outbreak in the community. Another purpose is to show that vaccination of these children will significantly reduce breathing problems (in the vaccinated children and unvaccinated people they come in contact with in the community) that require a visit to the doctor for treatment. Anoth... Read More
Gender:
ALL
Ages:
Between 4 years and 18 years
Trial Updated:
05/16/2017
Locations: Scott & White Hospital and Clinic, Temple, Texas +1 locations
Conditions: Influenza
Register for Updates
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
NCT01236040
Completed
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/09/2017
Locations: GSK Investigational Site, Anaheim, California +3 locations
Conditions: Influenza
Register for Updates
Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation
NCT01483274
Withdrawn
Patients with Acute Myelogenous Leukemia (AML) who relapse after an allogeneic stem cell transplant cell receive decitabine to up regulate cancer antigen expression, followed by a donor lymphocyte infusion and an autologous dendritic cell (DC). Vaccine Dendritic cells are pulsed with overlapping peptides derived from MAGE-A1, MAGE-A3, and NY-ESO-1.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2017
Locations: University of Louisville, Louisville, Kentucky
Conditions: Acute Myelogenous Leukemia
Register for Updates
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
NCT01934127
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine and placebo.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
05/04/2017
Locations: GSK Investigational Site, Miami, Florida +8 locations
Conditions: Influenza
Register for Updates
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
NCT02097849
Completed
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN). Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) \[a mostly T cell-independent humoral response\] and meningococcal polysaccharide dipht... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/01/2017
Locations: Research Site, Gilbert, Arizona +13 locations
Conditions: Relapsing Forms of Multiple Sclerosis
Register for Updates